Pharsight

Drugs that contain Osilodrostat Phosphate

1. Isturisa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8835646 RECORDATI RARE Organic compounds
Aug, 2026

(2 years from now)

US8314097 RECORDATI RARE Organic compounds
Mar, 2029

(4 years from now)

US9434754 RECORDATI RARE Use of an adrenal hormone-modifying agent
Jan, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8609862 RECORDATI RARE Use of an adrenal hormone-modifying agent
Jan, 2031

(6 years from now)

US10143680 RECORDATI RARE Pharmaceutical dosage forms
Jul, 2035

(11 years from now)

US10709691 RECORDATI RARE Pharmaceutical dosage forms
Oct, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 06, 2025
Orphan Drug Exclusivity(ODE-286) Mar 06, 2027

NCE-1 date: 06 March, 2024

Market Authorisation Date: 06 March, 2020

Treatment: Cushing's disease

Dosage: TABLET;ORAL

More Information on Dosage

ISTURISA family patents

Family Patents